DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Daranide (Dichlorphenamide) - Summary



DARANIDE® (dichlorphenamide tablets USP) is an oral carbonic anhydrase inhibitor.

DARANIDE ® (dichlorphenamide tablets USP) is indicated for the treatment of elevated intraoculr pressure.

See all Daranide indications & dosage >>


Published Studies Related to Daranide (Dichlorphenamide)

Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. [2000.01]
Although the carbonic anhydrase inhibitors have been used in the treatment of the primary periodic paralyses (PPs), their efficacy has not been demonstrated in double-blind, placebo-controlled trials. Therefore, we tested the efficacy of dichlorphenamide (DCP; Daranide), a potent carbonic anhydrase inhibitor, in the treatment of episodic weakness in the primary PPs...

more studies >>

Clinical Trials Related to Daranide (Dichlorphenamide)

Hyper- and Hypokalemic Periodic Paralysis Study [Completed]
The purpose of this study is to compare Dichlorphenamide with placebo (an inactive substance) for prevention of episodes and for improvement of strength in hyperkalemic (HYP) and hypokalemic (HOP) periodic paralysis. This study will also look at the long-term effects of Dichlorphenamide in periodic paralysis.

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders [Completed]
OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.

more trials >>

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017